Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
Milan RadovichJeffrey P SolzakChao J WangBradley A HancockSunil S BadveSandra K AlthouseSteven M BrayAnna Maria V StornioloTarah Jean BallingerBryan Paul SchneiderKathy D MillerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted.